• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database.利用一个大型的加拿大多机构数据库研究伴有病理T4原发性病变的IV期肾细胞癌的结局和预后因素。
Can Urol Assoc J. 2020 Feb;14(2):24-30. doi: 10.5489/cuaj.5941. Epub 2019 Jul 23.
2
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.嫌色细胞肾细胞癌(RCC):大型多中心系列中的肿瘤学结果和预后因素。
BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.
3
Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy.接受根治性肾切除术治疗的肾细胞癌伴邻近器官侵犯患者的预后指标及结局
Urol Oncol. 2016 May;34(5):237.e19-26. doi: 10.1016/j.urolonc.2015.11.020. Epub 2015 Dec 18.
4
Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.在接受减瘤性肾切除术和靶向治疗的转移性肾细胞癌中肉瘤样特征的预后意义
Am J Clin Exp Urol. 2022 Oct 15;10(5):327-333. eCollection 2022.
5
Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?剖析结果:对于伴有肉瘤样去分化的转移性肾细胞癌患者,是否应进行减瘤性肾切除术?
Front Oncol. 2021 Feb 10;10:627025. doi: 10.3389/fonc.2020.627025. eCollection 2020.
6
Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes.2型乳头状肾细胞癌与透明细胞肾细胞癌:生存结果
Eur J Surg Oncol. 2016 Nov;42(11):1744-1750. doi: 10.1016/j.ejso.2016.08.003. Epub 2016 Aug 22.
7
Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.肾细胞癌部分肾切除术中的手术切缘阳性:来自加拿大肾癌信息系统(CKCis)协作组的结果。
Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.
8
Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.靶向治疗时代接受减瘤性肾切除术患者生存相关因素的基于人群的分析。
Urol Oncol. 2014 Jul;32(5):561-8. doi: 10.1016/j.urolonc.2013.12.003. Epub 2014 Apr 4.
9
Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma.Ki-67指数和肉瘤样分化百分比是肉瘤样肾细胞癌的两个独立预后预测指标。
Cancer Manag Res. 2018 Nov 5;10:5339-5347. doi: 10.2147/CMAR.S176242. eCollection 2018.
10
Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.cT1-2/N0/M0期透明细胞肾细胞癌行微创部分肾切除术与微创根治性肾切除术的肿瘤学结局:一项倾向评分匹配分析
World J Urol. 2017 May;35(5):789-794. doi: 10.1007/s00345-016-1923-2. Epub 2016 Aug 30.

引用本文的文献

1
Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010.肾切除术改善了体能状态中等至良好的转移性肾细胞癌患者的生存状况——来自 2005 年至 2010 年芬兰全国基于人群的研究结果。
World J Surg Oncol. 2021 Jun 28;19(1):190. doi: 10.1186/s12957-021-02308-0.

本文引用的文献

1
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.舒尼替尼治疗同步转移性肾细胞癌患者中即刻与延迟细胞减瘤性肾切除术的比较:SURTIME 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
2
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.舒尼替尼单药治疗或肾细胞癌转移患者肾切除术后的治疗。
N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
3
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
4
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.辅助舒尼替尼治疗肾切除术后高危肾细胞癌:亚组分析和更新的总生存结果。
Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.
5
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.帕唑帕尼辅助治疗对比安慰剂用于局限性或局部进展性肾细胞癌患者肾切除术后的随机III期试验
J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.
6
Neoadjuvant therapy for localized and locally advanced renal cell carcinoma.局限性及局部进展性肾细胞癌的新辅助治疗
Urol Oncol. 2018 Jan;36(1):31-37. doi: 10.1016/j.urolonc.2017.07.015. Epub 2017 Aug 10.
7
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.探讨非透明细胞肾细胞癌的最佳治疗方法:一项比较VEGFR-TKIs与mTORi靶向治疗的随机临床试验的荟萃分析。
Eur J Cancer. 2017 Sep;83:237-246. doi: 10.1016/j.ejca.2017.06.030. Epub 2017 Jul 27.
8
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.高危局限性肾癌的辅助治疗:新证据与未来临床试验
J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4.
9
Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.非透明细胞肾细胞癌患者临床试验治疗的生存结局综合分析。
Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
10
A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma.一项比较腹腔镜手术与开放手术治疗pT3a期肾细胞癌的多中心倾向评分匹配分析
J Endourol. 2017 Jul;31(7):645-650. doi: 10.1089/end.2016.0787.

利用一个大型的加拿大多机构数据库研究伴有病理T4原发性病变的IV期肾细胞癌的结局和预后因素。

Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database.

作者信息

Oake Justin D, Patel Premal, Lavallée Luke T, Lattouf Jean-Baptiste, Saarela Olli, Klotz Laurence, Moore Ronald B, Kapoor Anil, Finelli Antonio, Rendon Ricardo A, Kawakami Jun, So Alan I, Drachenberg Darrel E

机构信息

Section of Urology, University of Manitoba, Winnipeg, MB, Canada.

Department of Urology, University of Miami, Miami, FL, United States.

出版信息

Can Urol Assoc J. 2020 Feb;14(2):24-30. doi: 10.5489/cuaj.5941. Epub 2019 Jul 23.

DOI:10.5489/cuaj.5941
PMID:31348746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7012283/
Abstract

INTRODUCTION

The primary objective of this study was to evaluate outcomes and prognosticators in patients who underwent radical nephrectomy (RN) or cytoreductive nephrectomy (CN), depending on the clinical stage of disease preoperatively, with a pathological T4 (pT4) renal cell carcinoma (RCC) outcome. There is little data on the outcome of this specific subset of patients.

METHODS

From 2009-2016, we identified patients in the Canadian Kidney Cancer information system (CKCis) who underwent RN or CN and were found to have pT4 RCC. Clinical, operative, and pathological variables were analyzed with univariable and multivariable Cox proportional hazard models to identify factors associated with overall survival (OS). Survival curves were created using Kaplan-Meier methods and compared using the log-rank test.

RESULTS

A total of 82 patients were included in the study cohort. Median patient age was 62 years (interquartile range [IQR] 55, 70). Fifty (61%) patients had clear-cell histology and 14 (17%) had sarcomatoid characteristics. Median followup was 12 months (IQR 3, 24). At last followup, eight (10%) patients are alive with no evidence of disease, 27 (33%) are alive with disease, four (5%) were lost to followup, 36 (44%) died of disease, and seven (8%) died of other causes. Tumor histological subtype (clear-cell vs. non-clear-cell) (p=0.0032), larger tumor size (cm) (p=0.012), and Fuhrman grade (G4 vs. G2-G3) (p=0.045) were significantly associated with mortality in a multivariable Cox regression model.

CONCLUSIONS

For patients with pT4 RCC after RN or CN, survival is poor. Sarcomatoid features, non-clear-cell histology, and presence of systemic symptoms were associated with worse OS.

摘要

引言

本研究的主要目的是根据术前疾病的临床分期,评估接受根治性肾切除术(RN)或减瘤性肾切除术(CN)且病理为T4(pT4)期肾细胞癌(RCC)患者的预后及预后因素。关于这一特定患者亚组的预后数据很少。

方法

2009年至2016年期间,我们在加拿大肾癌信息系统(CKCis)中识别出接受RN或CN且病理为pT4 RCC的患者。采用单变量和多变量Cox比例风险模型分析临床、手术和病理变量,以确定与总生存期(OS)相关的因素。使用Kaplan-Meier方法绘制生存曲线,并采用对数秩检验进行比较。

结果

研究队列共纳入82例患者。患者中位年龄为62岁(四分位间距[IQR]为55, 70)。50例(61%)患者为透明细胞组织学类型,14例(17%)具有肉瘤样特征。中位随访时间为12个月(IQR 3, 24)。在最后一次随访时,8例(10%)患者存活且无疾病证据,27例(33%)患者存活但有疾病,4例(5%)失访,36例(44%)死于疾病,7例(8%)死于其他原因。在多变量Cox回归模型中,肿瘤组织学亚型(透明细胞与非透明细胞)(p = 0.0032)、肿瘤较大尺寸(cm)(p = 0.012)和Fuhrman分级(G4与G2 - G3)(p = 0.045)与死亡率显著相关。

结论

对于接受RN或CN术后的pT4 RCC患者,生存率较低。肉瘤样特征、非透明细胞组织学类型及全身症状的存在与较差的OS相关。